Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AC-076
- Development stage
- Unknown
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Injection
01
Overview
AC-076 is a small molecule drug developed by Idorsia. Its precise mechanism of action is currently unknown. The compound has been evaluated in clinical trials as an injectable agent and reached Phase 1 development in healthy volunteers. There are no approved indications or known adverse events reported for this drug to date[1][2]. No active or inactive therapeutic areas have been disclosed.
02
Targets
EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on AC-076.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AC-076.